Disitamab Vedotin vs KJ015

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: HER2 · full Non-Small Cell Lung Cancer pipeline

Disitamab Vedotin

Marketed by RemeGen Co., Ltd. and partners

Phase 2 in Non-Small Cell Lung Cancerantibody-drug conjugate
Weak signal

NCT04311034 · Phase 1/2 · completed

The study was an uncontrolled, open-label single-arm trial of 37 participants, so it could not compare disitamab vedotin with placebo or another treatment. Its primary outcomes were clinical tumor measures, but the primary endpoint result has not been reported.

Next expected readout: June 2027 · NCT06734182 (registry estimate)

No aligned efficacy figure on record for this race.

KJ015

Developed by Shanghai Bao Pharmaceuticals Co., Ltd.

Phase 1 in Non-Small Cell Lung Cancerbispecific antibody (biparatopic)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2026 · NCT07036185 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointDisitamab VedotinKJ015
PFS, median—Not reported—Not reported
OS, median—Not reported—Not reported
ORR—Not reported—Not reported
Duration of response, median—Not reported—Not reported

PFS, median

Disitamab Vedotin
—Not reported
KJ015
—Not reported

OS, median

Disitamab Vedotin
—Not reported
KJ015
—Not reported

ORR

Disitamab Vedotin
—Not reported
KJ015
—Not reported

Duration of response, median

Disitamab Vedotin
—Not reported
KJ015
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Disitamab Vedotin: no structured comparison results are available for Non-Small Cell Lung Cancer.

KJ015: no structured comparison results are available for Non-Small Cell Lung Cancer.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Disitamab Vedotin's landscape · KJ015's landscape